Studying an extra COVID-19 vaccine dose in people with autoimmune diseases

An NIH study, co-led by a Michigan Medicine researcher, will follow participants over 13 months.

2:45 PM

Author | Noah Fromson

Nurse holding syringe vials with vaccine in clinic.

In recent months, mounting evidence has suggested the standard two-dose regimen for mRNA COVID-19 vaccines does not offer as much protection for immunocompromised people as it does for the general population.

Despite making up less than 3% of the U.S. adult population, immunocompromised people account for nearly 45% of breakthrough COVID-19 infections requiring hospitalization.

Given the available data, the Centers for Disease Control and Prevention has recommended that people who are moderately to severely immunocompromised receive a third dose of the mRNA vaccine. The FDA authorized the additional dose August 12.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.

The recommendation is based on a few studies that suggest immunocompromised people will produce higher levels of antibodies after a third dose. However, there are no control trials that focus specifically on the antibody responses to additional shots by those with autoimmune disease.

Now, a team of researchers co-led by a Michigan Medicine rheumatologist is launching a national trial to explore just that.

The focus of the study will be on Americans with autoimmune disease who did not present a strong immune response to two doses of the Pfizer-BioNTech vaccine, two doses of the Moderna vaccine or one dose of the Johnson & Johnson/Janssen vaccine. The Phase II trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. It will be co-led by Dinesh Khanna, M.B.B.S., M.Sc., the Frederick G.L. Huetwell professor of rheumatology and the director of the scleroderma program at Michigan Medicine.

"Although the FDA has recently approved booster vaccines for immunocompromised patients under emergency use authorization, there are several advantages for patients to participate in this 12-month adaptive trial design," Khanna said. "It allows us to carefully evaluate if the patients respond to the booster vaccine, continue to assess for durability of the vaccine over time and assess risk of flare of the underlying autoimmune disease."

The clinical trial to assess efficacy of a third COVID vaccine dose will include approximately 600 adult participants with one of five autoimmune diseases:

  • multiple sclerosis

  • pemphigus

  • rheumatoid arthritis

  • systemic lupus erythematosus

  • systemic sclerosis

Trial participants, who will be followed for 13 months, must be on immunosuppressive therapies and have demonstrated poor antibody response to an authorized COVID-19 vaccine regimen. Those medications include mycophenolate mofetil (MMF) or mycophenolic acid (MPA), methotrexate (MTX), or B cell-depleting drugs.

The research team will also examine whether pausing immunosuppressive medication improves immune response to the booster shot.

MORE FROM THE LAB: Subscribe to our weekly newsletter

"To hold or withhold the immunosuppressive therapies is an important issue for patients with autoimmune disease," Khanna said. "On one hand, it may improve the response to the booster, and on the other hand, it may lead to disease flare. This trial will carefully evaluate this in a controlled fashion."

Preliminary results are expected in November of 2021.

For more information about the COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders trial, go to and use NCT05000216 as an identifier.

More Articles About: Lab Report Covid-19 Immunizations Vaccines and Immunizations Immune Deficiency infectious disease
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories sketched out bacteria in a dish yellow and blue colors of U-M
Health Lab
This gross mixture has big benefits for the study of bacteria
Michigan Medicine researchers have found that growing bacteria on agar mixed with organs is an efficient and effective way to study infectious pathogens.
supar molecule teal blue yellow red
Health Lab
Immune protein suPAR links viral infection as possible cause of kidney disease
Through a series of experiments in non-human primates, mice and humans, a multi-institutional team led by researchers from Michigan Medicine and Rush University found that the immune protein soluble urokinase plasminogen activator receptor, or suPAR, is an important link between viral infections and proteinuria; the elevation of protein in the urine is known to cause glomerulopathy, a common form of kidney disease.
person holding walker with nurse next to them closer up on hands lower body
Health Lab
Long COVID happens in nursing homes, too
Post-acute sequelae of Sars-COV2 (PASC, long COVID) caused a decrease in independence and cognitive ability after coronavirus infection in nursing home residents
daycare kids running around in room
Health Lab
Child care centers aren’t a likely source of COVID-19 spread, study says
Research published from experts at Michigan Medicine, the University of Pittsburgh School of Medicine, and UPMC Children’s Hospital of Pittsburgh shows that children in daycare centers were not significant spreaders of COVID-19
wheelchair walker image
Health Lab
Spread of drug resistant bacteria linked to patient hand contamination and antibiotic use within nursing homes
A Michigan Medicine research team seeks to identify characteristics of patients within nursing homes, as well as the nursing home environment itself, that are associated with contamination by vancomycin-resistant enterococci.
mom in hospital bed holding newborn baby
Health Lab
RSV shot protects infants during peak season: What parents should know
For the first time, families will have a long acting option to protect infants and high risk toddlers from a common respiratory virus that sends tens of thousands of children to the hospital every year.